Article
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.
Journal of acquired immune deficiency syndromes (1999) - 15 Dec 2006
Pozniak Anton L, Gallant Joel E, DeJesus Edwin, Arribas Jose R, Gazzard Brian, Campo Rafael E, Chen Shan-Shan, McColl Damian, Enejosa Jeffrey, Toole John J, Cheng Andrew K
Abstract excerpt
BACKGROUND: In antiretroviral-naive patients, tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), and efavirenz (EFV) demonstrated superior outcomes compared with fixed-dose zidovudine (ZDV)/lamivudine (3TC) and EFV through 48 weeks. Results through a 96-week extension phase are presented. METHODS: In this randomized, open-label, noninferiority trial, 517 antiretroviral-naive HIV-infected patients received...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.